RECRUITINGINTERVENTIONAL
Modulating Movement Intention Via Cortical Stimulation
Modulating Movement Intention Via Cortical Stimulation in Healthy Subjects and Patients With Psychogenic Movement Disorders and Non-epileptic Seizures
About This Trial
The purpose of this protocol is to learn about movement intention and volition. To improve such knowledge, investigators will conduct sub-studies using multiple non-invasive methodologies. These results could provide preliminary data for subsequent studies evaluating local and global efficacy of plasticity-inducing treatments for PMD symptoms.
Who May Be Eligible (Plain English)
Who May Qualify:
(Healthy Controls)
- Fluent in English
(Patients with PMD or PNES):
- Diagnosis of PMD/PNES confirmed by a neurologist with expertise in movement disorders.
- Per the treating neurologist, subject is unlikely to require treatment and/or dosage changes for 3-6 months following screening
Who Should NOT Join This Trial:
- Any history of a significant neurological disorder, which may interfere with the interpretation of study data, as determined by the PI
- Chronic or progressive medical condition
- Any history of traumatic brain injury or significant head trauma
- Currently meets criteria for substance abuse or dependence
- History of any psychotic disorder or other psychiatric condition which may interfere with data interpretation
- Pregnancy
- Metal or devices in the head, including neurostimulators or metal foreign bodies
- Any other implanted metal device, including pacemaker, spinal cord stimulator, VNS.
- Any other ferromagnetic substance in the body that may increase study risk (including dental prosthetics, etc.).
- Taking tricyclic antidepressant or antiepileptic medications or CNS active drugs under "strong potential hazard" list in Rossi et al., 2009
- Current diagnosis of any inflammatory or autoimmune disorder within last 6 months
PMD and PNES Patients
- Any history of traumatic brain injury or significant head trauma
- Diagnosis of organic seizure disorder, including febrile seizures and tonic-clonic seizures;
- Neurological disorder other than PMD and PNES including stroke, fainting spells or syncope of unknown cause(s);
- Major or unstable medical illness, especially any current diagnosis of inflammatory or autoimmune disorders within last 6 months
- Metal or devices in the head, including neurostimulators or metal foreign bodies
- Taking tricyclic antidepressant medications or CNS active drugs under "strong potential hazard" list in Rossi et al., 2009;
- Diagnosis of dementia, or Montreal Cognitive Assessment (MoCA) ≤24;
...See full criteria on ClinicalTrials.gov
Always talk to your doctor about whether this trial is right for you.
Original Eligibility Criteria
View original clinical language
Inclusion Criteria:
(Healthy Controls)
* Fluent in English
(Patients with PMD or PNES):
* Diagnosis of PMD/PNES confirmed by a neurologist with expertise in movement disorders.
* Per the treating neurologist, subject is unlikely to require treatment and/or dosage changes for 3-6 months following screening
Exclusion Criteria:
* Any history of a significant neurological disorder, which may interfere with the interpretation of study data, as determined by the PI
* Chronic or progressive medical condition
* Any history of traumatic brain injury or significant head trauma
* Currently meets criteria for substance abuse or dependence
* History of any psychotic disorder or other psychiatric condition which may interfere with data interpretation
* Pregnancy
* Metal or devices in the head, including neurostimulators or metal foreign bodies
* Any other implanted metal device, including pacemaker, spinal cord stimulator, VNS.
* Any other ferromagnetic substance in the body that may increase study risk (including dental prosthetics, etc.).
* Taking tricyclic antidepressant or antiepileptic medications or CNS active drugs under "strong potential hazard" list in Rossi et al., 2009
* Current diagnosis of any inflammatory or autoimmune disorder within last 6 months
PMD and PNES Patients
* Any history of traumatic brain injury or significant head trauma
* Diagnosis of organic seizure disorder, including febrile seizures and tonic-clonic seizures;
* Neurological disorder other than PMD and PNES including stroke, fainting spells or syncope of unknown cause(s);
* Major or unstable medical illness, especially any current diagnosis of inflammatory or autoimmune disorders within last 6 months
* Metal or devices in the head, including neurostimulators or metal foreign bodies
* Taking tricyclic antidepressant medications or CNS active drugs under "strong potential hazard" list in Rossi et al., 2009;
* Diagnosis of dementia, or Montreal Cognitive Assessment (MoCA) ≤24;
* Recurrent visual hallucinations, within the past 6 months;
* History of significant uncontrollable movements of the head;
* Any clinically significant abnormality on vital signs
Treatments Being Tested
DEVICE
Sham TMS3 stimulation
half of the subjects will receive sham stimulation first
DEVICE
rTMS of left or right angular gyrus (AG) or frontal cortex (FC)
Half of the subjects will receive active stimulation first; A subject may receive either TMS or tDCS stimulation, but not both, over the course of the sub-study.
DEVICE
Anodal tDCS of left or right AG or FC
Half of the subjects will receive active stimulation first; A subject may receive either TMS or tDCS stimulation, but not both, over the course of the sub-study.
Locations (1)
New York University School of Medicine
New York, New York, United States